117 related articles for article (PubMed ID: 38453260)
21. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
Kassab AE; Hassan RA
Bioorg Chem; 2018 Oct; 80():531-544. PubMed ID: 30014921
[TBL] [Abstract][Full Text] [Related]
22. Half-Lantern Cyclometalated Platinum(II) Complexes as Anticancer Agents: Molecular Docking, Apoptosis, Cell Cycle Analysis, and Cytotoxic Activity Evaluations.
Hajipour F; Mahdavinia M; Fereidoonnezhad M
Anticancer Agents Med Chem; 2022; 22(6):1149-1158. PubMed ID: 34259151
[TBL] [Abstract][Full Text] [Related]
23. New Quinoxaline-Based Derivatives as PARP-1 Inhibitors: Design, Synthesis, Antiproliferative, and Computational Studies.
Syam YM; Anwar MM; Abd El-Karim SS; Elokely KM; Abdelwahed SH
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956876
[TBL] [Abstract][Full Text] [Related]
24. Cell Cycle Arrest and Apoptosis-Inducing Ability of Benzimidazole Derivatives: Design, Synthesis, Docking, and Biological Evaluation.
Nazreen S; Almalki ASA; Elbehairi SEI; Shati AA; Alfaifi MY; Elhenawy AA; Alsenani NI; Alfarsi A; Alhadhrami A; Alqurashi EA; Alam MM
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296495
[TBL] [Abstract][Full Text] [Related]
25. Novel quinoxaline-based VEGFR-2 inhibitors to halt angiogenesis.
Ismail MMF; Shawer TZ; Ibrahim RS; Allam RM; Ammar YA
Bioorg Chem; 2023 Oct; 139():106735. PubMed ID: 37531818
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, molecular modeling, in vivo study and anticancer activity against prostate cancer of (+) (S)-naproxen derivatives.
Birgül K; Yıldırım Y; Karasulu HY; Karasulu E; Uba AI; Yelekçi K; Bekçi H; Cumaoğlu A; Kabasakal L; Yılmaz Ö; Küçükgüzel ŞG
Eur J Med Chem; 2020 Dec; 208():112841. PubMed ID: 32998089
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
28. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (TRKA) Inhibitors: Synthesis, Anticancer Activities,
Alam MS; Lee DU
Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
30. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract][Full Text] [Related]
31. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of 1-phenyl-4,6-dihydrobenzo[b]pyrazolo[3,4-d]azepin-5(1H)-one/thiones as anticancer agents.
Parupalli R; Akunuri R; Spandana A; Phanindranath R; Pyreddy S; Bazaz MR; Vadakattu M; Joshi SV; Bujji S; Gorre B; Yaddanapudi VM; Dandekar MP; Reddy VG; Nagesh N; Nanduri S
Bioorg Chem; 2023 Jun; 135():106478. PubMed ID: 36958121
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
34. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
[TBL] [Abstract][Full Text] [Related]
35. Design and Synthesis of Non-Covalent Imidazo[1,2-
Kumar M; Joshi G; Arora S; Singh T; Biswas S; Sharma N; Bhat ZR; Tikoo K; Singh S; Kumar R
Molecules; 2021 Mar; 26(5):. PubMed ID: 33803355
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, Molecular Docking, and 2D-QSAR Modeling of Quinoxaline Derivatives as Potent Anticancer Agents against Triple-negative Breast Cancer.
Kaushal T; Khan S; Fatima K; Luqman S; Khan F; Negi AS
Curr Top Med Chem; 2022; 22(10):855-867. PubMed ID: 35331094
[TBL] [Abstract][Full Text] [Related]
37. Novel Hydrazone Derivatives of 3-Bromopyruvate: Synthesis, Evaluation of the Cytotoxic Effects, Molecular Docking and ADME Studies.
Beygi F; Mostoufi A; Mojaddami A
Chem Biodivers; 2022 Jun; 19(6):e202100754. PubMed ID: 35427437
[TBL] [Abstract][Full Text] [Related]
38. Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.
AboulWafa OM; Daabees HMG; El-Said AH
Bioorg Chem; 2023 May; 134():106437. PubMed ID: 36842320
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and molecular docking studies of novel quinoxaline derivatives as anticancer agents.
Ali SH; Osmaniye D; Sağlık BN; Levent S; Özkay Y; Kaplancıklı ZA
Chem Biol Drug Des; 2023 Aug; 102(2):303-315. PubMed ID: 37094830
[TBL] [Abstract][Full Text] [Related]
40. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors.
Desai S; Desai V; Shingade S
Bioorg Chem; 2020 Jan; 94():103382. PubMed ID: 31662214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]